4//SEC Filing
Chen Yixin 4
Accession 0001415889-25-010981
CIK 0001346830other
Filed
Apr 16, 8:00 PM ET
Accepted
Apr 17, 6:50 PM ET
Size
6.9 KB
Accession
0001415889-25-010981
Insider Transaction Report
Form 4
Chen Yixin
VP, Chem, Mfg and Ctrls
Transactions
- Award
Employee Stock Option (right to buy)
2025-04-15+14,752→ 14,752 totalExercise: $4.70Exp: 2031-12-15→ Common Stock (14,752 underlying)
Footnotes (3)
- [F1]25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
- [F2]Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
- [F3]Received in exchange for a stock option to acquire 110,000 shares of common stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement").
Documents
Issuer
Tvardi Therapeutics, Inc.
CIK 0001346830
Entity typeother
Related Parties
1- filerCIK 0002064987
Filing Metadata
- Form type
- 4
- Filed
- Apr 16, 8:00 PM ET
- Accepted
- Apr 17, 6:50 PM ET
- Size
- 6.9 KB